ABSTRACT
Objective To investigate the changes of plasma miR-29a level in patients with hepatocellular carcinoma(HCC) and its clinical significance.Methods Case-control study,30 patients with HCC,30 patients with cirrhosis of liver (LC) and 30 healthy controls (HC) were recruited from Shiyan Taihe Hospital,2016 January to June.The level of microRNA-29a (miR-29a) in plasma was detected by real time quantitative PCR,and the sensitivity and specificity of plasma miR-29a expression in the diagnosis of HCC were analyzed by receiver operating characteristic curve (ROC),and to analyze the correlation between the miR-29a and the alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma,the combination of miR-29a and AFP could improve the diagnostic efficiency of HCC.Results The relative expression of miR-29a was significantly different between HCC group (3.38±8.37),LC group (8.79±3.80) and HC group (11.98±6.64),the expression level of miR-29a in HCC group was significantly lower than that in LC group (P=0.046) and HC group (P=0.001),and that in LC group was significantly lower than that in HC group (P=0.026).The area under the ROC curve of miR-29a was 0.816 (95％ CI 0.695 to 0.938) less than AFP 0.918 (95％ CI 0.853 to 0.982),and the diagnostic efficiency of miR-29a was not as good as that of AFP.The levels of miR-29a and AFP in plasma of patients with hepatocellular carcinoma were significantly correlated (P=0.002).Conclusion The level of miR 29a in plasma of patients with HCC decreased,which may become the reference index of HCC diagnosis.
ABSTRACT
MicroRNA (miRNA) is an important gene regulatory molecule involved in the occurrence of a variety of diseases and is relat-ed to tumors. MicroRNA has become a new direction of oncology research in recent years. Studies showed that miR-29 plays dual roles, as tumor suppressor and tumor promoter. The expression of miR-29 significantly differs between cancer and normal tissues. miR-29 is predicted to be a biomarker for early diagnosis and prognosis prediction of certain cancer. This paper reviews the role of miR-29 in the pathogenesis of cancer.